Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- depressed mood
- anhedonia
- functional impairment
Other diagnostic factors
- weight change
- libido changes
- sleep disturbance
- changes in movement
- low energy
- excessive guilt
- poor concentration
- suicidal ideation
- bipolar disorder excluded
- substance abuse/medication side effects excluded
- medical illness excluded
- schizophrenia excluded
Risk factors
- postnatal status
- personal or family history of depressive disorder or suicide
- dementia
- corticosteroids
- interferon
- propranolol
- oral contraceptives
- co-existing medical conditions
- female sex
- comorbid substance use
- personality disorders
- stressful life events
- obesity
Diagnostic investigations
1st investigations to order
- clinical diagnosis
- metabolic panel
- FBC
- thyroid function tests
- Patient Health Questionnaire-2 (PHQ-2)
- Patient Health Questionnaire-9 (PHQ-9)
- Edinburgh Postnatal Depression Scale
- Geriatric Depression Scale
- Cornell Scale for Depression in Dementia
Investigations to consider
- 24-hour free cortisol
- vitamin B12
- folic acid
Treatment algorithm
severe depression, non-pregnant: psychotic, suicidal, severe psychomotor retardation impeding activities of daily living, catatonia, or severe agitation
moderate depression, non-pregnant: severe symptoms, significant impairment but no psychotic symptoms, no suicidal ideation, and no severe psychomotor retardation or agitation
mild depression, non-pregnant: low to moderate severity symptoms, partial impairment, no psychotic symptoms, no suicidal ideation, and no psychomotor retardation or agitation
treatment-resistant/refractory depression
pregnant
treatment responsive
recurrent episode
Contributors
Authors
Dean F. MacKinnon, MD
Associate Professor
Psychiatry and Behavioral Sciences
The Johns Hopkins Hospital
Baltimore
MD
Disclosures
DFM declares that he has no competing interests.
Acknowledgements
Dr Dean F. MacKinnon would like to gratefully acknowledge Dr Roger S. McIntyre, Dr Tonya Fancher, and Dr Richard Kravitz, the previous contributors to this topic.
Disclosures
RSM has received research funds from Stanley Medical Research Institute and National Alliance for Research on Schizophrenia and Depression (NARSAD). RSM is on the advisory board for AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen-Ortho, Solvay/Wyeth, Eli Lilly, Organon, Lundbeck, Biovail, Pfizer, Shire, and Schering-Plough. RSM is on the Speakers Bureau for Janssen-Ortho, AstraZeneca, Eli Lilly, Lundbeck, Biovail, and Wyeth. RSM has received research grants from Eli Lilly, Janssen-Ortho, Shire, and AstraZeneca. RSM has received travel funds from Bristol-Myers Squibb. TF declares that she has no competing interests. RK has received research grants from Pfizer on non-depression-related topics.
Peer reviewers
Scott McAfee, MD
Director
Residency Training
St Vincent's Hospital
Manhattan
NY
Disclosures
SM declares that he has no competing interests.
Dietmar Winkler, MD
Department of Psychiatry and Psychotherapy
Medical University of Vienna
Vienna
Austria
Disclosures
DW has received lecture fees from CSC Pharmaceuticals, GlaxoSmithKline, and Pfizer, and has served as a consultant for GlaxoSmithKline.
Differentials
- Adjustment disorder with depressed mood
- Substance-/medication- or medical illness-associated and other depressive disorders
- Bipolar disorder
More DifferentialsGuidelines
- Nonpharmacologic and pharmacologic treatment of adults in the acute phase of major depressive disorder
- Treatment and management of mental health conditions during pregnancy and postpartum
More GuidelinesPatient information
Depression in adults: what is it?
Depression in adults: what treatments work?
More Patient informationCalculators
Geriatric Depression Scale
Depression (any) Screening by a Two Item PHQ-2
More Calculators- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer